EUCTR2007-002909-49-IT进行中（未招募）不适用
eoadjuvant chemotherapy in patients affected by prostatic cancer locally advanced (non metastatic. Phase II study - ND
G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST0 个研究点开始时间: 2007年10月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Histologically proven prostate adenocarcinoma Er MRI to assess the disease extension and the prostate volume (endo-rectal), eventually Total PSA ≥ 20 ng/ml e ≤ 50 ng/ml and patients with PSA ≥ 50 ng/ml excluded. Other criteria described by nomograms findable on the website http//www.nomograms.org; Gleason score 8-10 by prostatic mapping T3a clinical staging Eventual presence of locoregional lynphonodal Cromogranin A Testosteron evaluation Bone scan if it suspects skeletal metastasis Coline TC-PET (to execute TC-PET to the beginning and the end of the treatment to estimate the pathologic staging; naturally to repeat the TC-PET to the end of treatment if to the beginning the TC-PET turned out positive) Age years:18 ≥ ≤ 75 Estimated life expectancy of at least 6 months Performance status ≤ 2 Adeguate bone marrow, renal and liver function: neutrophles count ≥ 1,500/mm3; platelets ≥ 100,000/mm3; haemoglobin ≥ 10 g/dL; bilirubin <1.5 times above normal ranges; AST/ALT <1.5 times above normal ranges; creatinine ≥ 1.5 mg/dl. Written informed consent Absence of anypsychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule The patients must be all making radical surgery in the case of positive margine they should make adjuvant radiotherapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Distant metastases Active uncontrolled infections requiring intravenous antibiotic therapy Active peptic ulcer, uncontrolled diabetes mellitus or other controindications for cortisonic therapy Presence of any clinically significant cardiac arrhythmia, congestive heart failure (LVEF < 40%), myocardial infaction, unstable angina or coronary artery bypass graft in the previous six months Other severe or chronic medical or psychiatric condition that would impart, in the judgement of the investigator, excess risk associated with study participation or would make the patient inappropriate for entry into this study Other concomitant malignancies (other than treated carcinomas of the skin different from melanoma or other malignancies treated with curative intent) and no evidence of disease since, at least, five years Patients with extension extracapsulare disease at first diagnosis.
研究者
相似试验
招募中
2 期
Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: Multicentric Phase II Study2024-517183-31-00Centro Di Riferimento Oncologico Di Aviano93
招募中
不适用
Adjuvant chemotherapy in the patients with stage II colon cancer that have MSI-H status and poor prognostic factors : to give or not to give?To find out if the patients with stage II colon cancer that have MSI-H and poor prognostic factors gain the survival benefit (disease-free and overall survival) of adjuvant chemotherapy or notStage IIPoor prognostic factorMSIadjuvant chemotherapyColon cancerTCTR20180329003Ratchadapiseksompoch200
已完成
2 期
Adjuvant chemotherapy for completely rsected non-small cell lung cancer with TS-1 - evaluation of predictive factors for prognosiscompletely resected non-small cell lung cancerJPRN-UMIN000001049Division of General Thoracic Surgery, Keio University, School of Medicine,200
已完成
3 期
Phase III Study of adjuvant chemotherapy for the patients resected pathological stage I(T1>2cm) Non Small Cell Lung Cancer (JCOG0707)JPRN-UMIN000001494Japan Clinical Oncology Group(JCOG)960
已完成
不适用
Phase I Study of adjuvant chemotherapy for the patients resected pathological stage IA(T1>2cm) Non Small Cell Lung Cancer (SLCG0701)JPRN-UMIN000006967Setouchi Lung Cancer Group80